Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions

Neurology. 2024 Sep 10;103(5):e209739. doi: 10.1212/WNL.0000000000209739. Epub 2024 Aug 6.

Authors

Samantha A Banks¹, Waleed Brinjikji¹, Caterina Giannini¹, Stephanie B Syc-Mazurek¹, Helena K Xeros¹, Michel Toledano¹, Rafid Mustafa¹, Ivan D Carabenciov¹, W Oliver Tobin¹

Affiliation

¹ From the Departments of Neurology (S.A.B., S.B.S-M., H.K.X., M.T., R.M., I.D.C., W.O.T.), Radiology (W.B.), Anatomic Pathology (C.G.), and Center for MS and Autoimmune Neurology (W.O.T.), Mayo Clinic, Rochester, MN.

PMID: 39106425
DOI: 10.1212/WNL.0000000000209739

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Female
Humans
Magnetic Resonance Imaging
Male
Melphalan* / administration & dosage
Melphalan* / therapeutic use
Multiple Sclerosis* / diagnostic imaging
Multiple Sclerosis* / drug therapy
Myeloablative Agonists / administration & dosage

Substances

Melphalan
Myeloablative Agonists